Stock Analysis

SofWave Medical First Quarter 2024 Earnings: US$0.029 loss per share (vs US$0.11 loss in 1Q 2023)

TASE:SOFW
Source: Shutterstock

SofWave Medical (TLV:SOFW) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$13.2m (up 27% from 1Q 2023).
  • Net loss: US$983.0k (loss narrowed by 74% from 1Q 2023).
  • US$0.029 loss per share (improved from US$0.11 loss in 1Q 2023).
earnings-and-revenue-history
TASE:SOFW Earnings and Revenue History May 11th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

SofWave Medical shares are up 3.4% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with SofWave Medical, and understanding it should be part of your investment process.

Valuation is complex, but we're helping make it simple.

Find out whether SofWave Medical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.